Clinical Trials Browser

Medulloblastoma × Eflornithine × 90 days × Clear all

NCT04696029 2026-04-28

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Phase 2 Recruiting

Medulloblastoma